References
- Saborido-Fiaño R, Martinón-Torres N, Crujeiras-Martinez V, Couce ML, Leis R. Letter to the editor concerning the article ‘Safety of vaccines administration in hereditary fructose intolerance’. Hum Vaccin Immunother. 2021 Mar;2:1–2. doi:10.1080/21645515.2021.1891816.
- Maiorana A, Sabia A, Corsetti T, Dionisi-Vici C. Safety of vaccines administration in hereditary fructose intolerance. Orphanet J Rare Dis. 2020;15(1):274. doi:10.1186/s13023-020-01552-z.
- Gallo G, Mel R, Ros E, Filia A (Ed.) Guida alle controindicazioni alle vaccinazioni (aggiornamento 2018). Roma (Italy): Istituto Superiore di Sanità; 2019. (Rapporti ISTISAN 19/3).
- Pelliccia M, Andreozzi P, Paulose J, D’Alicarnasso M, Cagno V, Donalisio M, Civra A, Broeckel RM, Haese N, Jacob Silva P, et al. Additives for vaccine storage to improve thermal stability of adenoviruses from hours to months. Nat Commun. 2016;7:13520. doi:10.1038/ncomms13520.
- Wolfson LJ, Gasse F, Lee-Martin SP, Lydon P, Magan A, Tibouti A, Johns B, Hutubessy R, Salama P, Okwo-Bele JM. Estimating the costs of achieving the WHO-UNICEF global immunization vision and strategy, 2006-2015. Bull World Health Organ. 2008;86(1):27–39. doi:10.2471/BLT.07.045096.
- Lee BY, Cakouros BE, Assi TM, Connor DL, Welling J, Kone S, Djibo A, Wateska AR, Pierre L, Brown ST, et al. The impact of making vaccines thermostable in Niger’s vaccine supply chain. Vaccine. 2012;30(38):5637–43. doi:10.1016/j.vaccine.2012.06.087.
- Gupta CK, Leszczynski J, Gupta RK, Siber GR. Stabilization of respiratory syncytial virus (RSV) against thermal inactivation and freeze-thaw cycles for development and control of RSV vaccines and immune globulin. Vaccine. 1996;14(15):1417–20. doi:10.1016/S0264-410X(96)00096-5.
- Croyle MA, Cheng X, Wilson JM. Development of formulations that enhance physical stability of viral vectors for gene therapy. Gene Ther. 2001;8:1281–90. doi:10.1038/sj.gt.3301527.
- Evans RK, Nawrocki DK, Isopi LA, Williams DM, Casimiro DR, Chin S, Chen M, Zhu D-M, Shiver JW, Volkin DB, et al. Development of stable liquid formulations for adenovirus based vaccines. J Pharm Sci. 2004;93:2458–75. doi:10.1002/jps.20157.
- Braga SS, Barbosa JS, Santos NE, El-Saleh F, Paz FAA. Cyclodextrins in antiviral therapeutics and vaccines. Pharmaceutics. 2021;13(3):409. doi:10.3390/pharmaceutics13030409.
- Quaak SG, Haanen JB, Beijnen JH, Nuijen B. Naked plasmid DNA formulation: effect of different disaccharides on stability after lyophilisation. AAPS PharmSciTech. 2010;11:344–50. doi:10.1208/s12249-010-9391-2.
- Yoshioka S, Miyazaki T, Aso Y, Kawanishi T. Significance of local mobility in aggregation of beta-galactosidase lyophilized with trehalose, sucrose or stachyose. Pharm Res. 2007;24:1660–67. doi:10.1007/s11095-007-9296-2.
- Davis ME, Brewster ME. Cyclodextrin-based pharmaceutics: past, present and future. Nat Rev Drug Discov. 2004;3:1023–35. doi:10.1038/nrd1576.
- Rincón-López J, Almanza-Arjona YC, Riascos AP, Rojas-Aguirre Y. Technological evolution of cyclodextrins in the pharmaceutical field. J Drug Deliv Sci Technol. 2021;61:102156. doi:10.1016/j.jddst.2020.102156.
- Kim AI, Akers MJ, Nail SL. The physical state of mannitol after freeze-drying: effects of mannitol concentration, freezing rate, and a noncrystallizing cosolute. J Pharm Sci. 1998;87:931–35. doi:10.1021/js980001d.
- Bouteldja N, Timson DJ. The biochemical basis of hereditary fructose intolerance. J Inherit Metab Dis. 2010;33(2):105–12. doi:10.1007/s10545-010-9053-2.
- Gaughan S, Ayres L, Baker PR II. Hereditary fructose intolerance. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, editors. GeneReviews® [Internet]. Seattle: University of Washington; 2015 Dec 17. p. 1993–2021. [Updated 2021 Feb 18]; accessed 2021 April 24]. https://www.ncbi.nlm.nih.gov/books/NBK333439/;.
- Cox TM. Aldolase B and fructose intolerance. FASEB J. 1994;8:62–71. doi:10.1096/fasebj.8.1.8299892.
- EMA authorized vaccines. [accessed 2021 April 23]. https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines/vaccines-covid-19/covid-19-vaccines-authorised#authorised-covid-19-vaccines-section;.
- FDA authorized vaccines. [accessed 2021 April 24]. https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/covid-19-vaccines;.
- British medicines & healthcare products regulatory agency authorized vaccines. [accessed 2021 April 23]. https://www.gov.uk/government/collections/mhra-guidance-on-coronavirus-covid-19;
- Pfizer-BioNTech COVID-19 vaccine fact sheet for healthcare providers administering vaccine. [accessed 2021 May 19]. http://labeling.pfizer.com/ShowLabeling.aspx?id=14471.
- Moderna COVID-19 vaccine fact sheet for healthcare providers administering vaccine. [accessed 2021 May 19]. https://www.modernatx.com/covid19vaccine-eua/eua-fact-sheet-providers.pdf.
- AstraZeneca ChAdOx1 nCoV-19 vaccine safety data sheet. [accessed 2021 May 19]. https://www.astrazeneca.com.au/content/dam/az-au/AZD1222%20SDS%2025943%20v1-1%2016SEP20.pdf.
- The Janssen covid-19 Vaccine fact sheet for healthcare providers administering vaccine. [accessed 2021 May 19]. https://www.janssenlabels.com/emergency-use-authorization/Janssen+COVID-19+Vaccine-HCP-fact-sheet.pdf.